BASF-Purac JV Starts Bio-Succinic Acid Plant in Spain

Succinity, a joint venture of Corbion Purac and BASF for bio-based succinic acid, has started up of its first commercial production facility at Corbion Purac's Montmeló, Spain, site. Output of 10,000 t/y is designed to supply the global market.

The joint venture, which is headquartered at Düsseldorf, Germany, is also planning a second large-scale facility, with details to be announced following a successful market introduction of the products. Earlier, Succinity hinted at a 50,000 t/y capacity.

The process is based on the proprietary microorganism Basfia succiniciproducens, which the company said allows for flexible feedstock use. Thanks to a closed-loop process, the bio-succinic acid can be produced efficiently without major waste streams, it added. 

Philipp Walter, managing director of Succinity, said the start-up of the company's first commercial facility represents a "key milestone" in its plan to become a major producer of the renewable acid.

BASF and Corbion Purac have cooperated on product development of bio-based succinic acid, being recommended as a versatile building block for chemical intermediates, since 2009. The acid is claimed to be suitable for a variety of potential applications, such as the biopolymer polybutylene succinate (PBS), as well as polyurethanes, coatings and life science products.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.